Exosomes: Natural carriers for siRNA delivery

Current Pharmaceutical Design

Volumn 21, Issue 31, 2015, Pages 4556-4565

  Kumar, Lalit ^a,b   Verma, Shivani ^c   Vaidya, Bhuvaneshwar ^d   Gupta, Vivek ^d  

^a Shivalik College of Pharmacy   (India)

^b I K GUJRAL PUNJAB TECHNICAL UNIVERSITY   (India)

^c Rayat Bahra Institute of Pharmacy   (India)

^d KECK GRADUATE INSTITUTE   (United States)

Author keywords

Endogenous; Exosomes; Extracellular vesicles; Oligonucleotide; Small interfering RNA

Indexed keywords

ASVASIRAN; CD63 ANTIGEN; CD81 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; CERAMIDE; CHOLESTEROL; GLYCEROPHOSPHOLIPID; GUANOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LIPOSOME; MANNOSE; MICRORNA; SIALIC ACID; SMALL INTERFERING RNA; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; OLIGONUCLEOTIDE;

CELL COMMUNICATION; ELECTROPORATION; EXOCYTOSIS; EXOSOME; PATENT; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; ULTRACENTRIFUGATION; ULTRAFILTRATION; ANIMAL; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; EXOSOMES; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LIPOSOMES; OLIGONUCLEOTIDES; RNA, SMALL INTERFERING;

EID: 84946743099     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282131151013190112     Document Type: Review

References (82)

1. [1] Susan MVD, Pieter V, Samira L, et al. Microvesicles andexosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release 2012; 161: 635-44.
2. [2] Denzer K, Kleijmeer MJ, Heijnen HF, et al. Exosome: from internalvesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113: 3365-374.
3. [3] Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: arte-facts no more. Trends Cell Biol 2009; 19: 43-51.
4. [4] Thery C, Zitvogel L, Amigorena S. Exosomes: composition, bio-genesis and function. Nat Rev Immunol 2002; 2: 569-79.
5. [5] Trams EG, Lauter CJ, Salem N, et al. Exfoliation of membraneecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta 1981; 645: 63-70.
6. [6] Pan BT, Teng K, Wu C, et al. Electron microscopic evidence forexternalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 1985; 101: 942-8.
7. [7] Hurley JH, Boura E, Carlson LA, et al. Membrane budding. Cell 2010; 143: 875-87.
8. [8] Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyorsof immune responses. Nat Rev Immunol 2009; 9: 581-93.
9. [9] Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell:an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev 2013; 65: 336-41.
10. [10] Thery C, Duban L, Segura E, et al. Indirect activation of naiveCD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3: 1156-62.
11. [11] Thery C, Regnault A, Garin J, et al. Molecular characterization ofdendritic cell-derived exosomes. Selective accumulation of the heat-shock protein hsc73. J Cell Biol 1999; 147: 599-610.
12. [12] Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets releasetwo types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and-granules. Blood 1999; 94: 3791-9.
13. [13] Kooijmans SA, Vader P, van Dommelen SM, et al. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomed 2012; 7: 1525-41.
14. [14] Sokolova V, Ludwig AK, Hornung S, et al. Characterisation ofexosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B Biointerfaces 2011; 87: 146-50.
15. [15] Conde-Vancells J, Rodriguez-Suarez E, Embade N, et al. Charac-terization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res 2008; 7: 5157-66.
16. [16] Subra C, Grand D, Laulagnier K, et al. Exosomes account for vesi-cle-mediated transcellular transport of activatable phospholipases and prostaglandins. J Lipid Res 2010; 51: 2105-20.
17. [17] Vlassov AV, Magdaleno S, Setterquist R, et al. Exosomes: currentknowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012; 1820: 940-8.
18. [18] Wubbolts R, Leckie RS, Veenhuizen PT, et al. Proteomic and bio-chemicalanalyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 2003; 278: 10963-72.
19. [19] Batista BS, Eng WS, Pilobello KT, et al. Identification of a con-served glycan signature for microvesicles. J Proteome Res 2011; 10: 4624-33.
20. [20] Zomer A, Vendrig T, Hopmans ES, et al. Exosomes: fit to deliversmall RNA. Commun Integr Biol 2010; 3: 447-50.
21. [21] Valadi H, Ekstrom K, Bossios A, et al. Exosome mediated transferof mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
22. [22] Thery C, Amigorena S, Raposo G, et al. Isolation and characteriza-tion of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006; 3: 22-30.
23. [23] Cheruvanky A, Zhou H, Pisitkun T, et al. Rapid isolation of urinaryexosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am J Physiol Renal Physiol 2007; 292: 1657-61.
24. [24] Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC re-duces myocardial ischemia/reperfusion injury. Stem Cell Res 2010; 4: 214-22.
25. [25] Adams A. Concentration of Epstein-Barr virus from cell culturefluids with polyethylene glycol. J Gen Virol 1973; 20: 391-4.
26. [26] Lewis GD, Metcalf TG. Polyethylene glycol precipitation for re-covery of pathogenic viruses, including Hepatitis A virus and human Rotavirus, from oyster, water, and sediment samples. Appl Environ Microbiol 1998; 4: 1983-8.
27. [27] Chen C, Skog J, Hsu CH, et al. Microfluidic isolation and transcrip-tome analysis of serum microvesicles. Lab Chip 2010; 10: 505-11.
28. [28] Lakkaraju A, Rodriguez-Boulan E. Itinerant exosomes: emergingroles in cell and tissue polarity. Trends Cell Biol 2008; 18: 199-209.
29. [29] Johnstone RM. Exosomes biological significance: a concise review. Blood Cells Mol Dis 2006; 36: 315-21.
30. [30] Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Mi-crovesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113: 752-60.
31. [31] Pegtel DM, van de Garde MD, Middeldorp JM. Viral miRNAsexploiting the endosomal-exosomal pathway for intercellular cross-talk and immune evasion. Biochim Biophys Acta 2011; 1809: 715-21.
32. [32] Belting M, Wittrup A. Nanotubes, exosomes, and nucleic acid-binding peptides provide novel mechanisms of intercellular communication in eukaryotic cells: implications in health and disease. J Cell Biol 2008; 183: 1187-91.
33. [33] Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer ofthe oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10: 619-24.
34. [34] Pegtel DM, van de Garde MD, Middeldorp JM. Viral miRNAsexploiting the endosomal-exosomal pathway for intercellular cross-talk and immune evasion. Biochim Biophys Acta 201; 1809: 715-21.
35. [35] Schroeder A, Levins CG, Cortez C, et al. Lipid based nanothera-peutics for siRNA delivery. J Intern Med 2010; 267: 9-21.
36. [36] Zhang H, Kolb FA, Jaskiewicz L, et al. Single processing centermodels for human Dicer and bacterial RNase III. Cell 2004; 118: 57-68.
37. [37] Check E. Hopes rise for RNA therapy as mouse study hits target. Nature 2004; 432: 136.
38. [38] Garbuzenko OB, Saad M, Betigeri S, et al. Intratracheal versusintravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 2009; 26: 382-94.
39. [39] Davidson BL, Paulson HL. Molecular medicine for the brain: si-lencing of disease genes with RNA interference. Lancet Neurol 2004; 3: 145-9.
40. [40] Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: per-spectives on the fundamental and phenomenological distinctionsExosomes: Natural Carriers for siRNA Deliveryfrom polymer-based DNA delivery. J Control Release 2007; 121: 64-73.
41. [41] Bartlett DW, Davis ME. Insights into the kinetics of siRNA medi-ated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006; 34: 322-33.
42. [42] Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009; 109: 259-302.
43. [43] Juliano R, Alam MR, Dixit V, et al. Mechanisms and strategies foreffective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008; 36: 4158-71.
44. [44] Wang J, Lu Z, Guillaume WM, et al. Delivery of siRNA therapeu-tics: barriers and carriers. AAPS J 2010; 12: 492-503.
45. [45] van de Water FM, Boerman OC, Wouterse AC, et al. Intravenouslyadministered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006; 34: 1393-7.
46. [46] Bochicchio S, Dalmoro A, Barba AA, et al. Liposomes as siRNADelivery Vectors. Curr Drug Metab 2015 (In press).
47. [47] Tahara K, Yamamoto H, Hirashima N, et al. Chitosan-modifiedpoly(D, L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm 2010; 74: 421-6
48. [48] Navarro G, Pan J, Torchilin VP. Micelle-like Nanoparticles asCarriers for DNA and siRNA. Mol Pharm 2015; 12: 301-13.
49. [49] Liu H, Li Y, Mozhi A, et al. SiRNA-phospholipid conjugates forgene and drug delivery in cancer treatment. Biomaterials 2014; 35: 6519-33.
50. [50] Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistentin vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-7.
51. [51] Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing ofan endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-8.
52. [52] Lu JJ, Langer R, Chen J. A novel mechanism is involved in cationiclipid-mediated functional siRNA delivery. Mol Pharm 2009; 6: 763-71.
53. [53] de Martimprey H, Vauthier C, Malvy C, et al. Polymer nanocarriersfor the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm 2009; 71: 490-504.
54. [54] Nguyen J, Steele TW, Merkel O, et al. Fast degrading polyesters assiRNA nano-carriers for pulmonary gene therapy. J Control Release. 2008; 132: 243-51.
55. [55] Khan A, Benboubetra M, Sayyed PZ, et al. Sustained polymericdelivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004; 12: 393-404.
56. [56] Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989; 337: 387-8.
57. [57] Han SE, Kang H, Shim GY, et al. Novel cationic cholesterol de-rivative-based liposomes for serum-enhanced delivery of siRNA. Int J Pharm 2008; 353: 260-9.
58. [58] Jevprasesphant R, Penny J, Jalal R, et al. The influence of surfacemodification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003; 252: 263-6.
59. [59] Patil ML, Zhang M, Taratula O, et al. Internally cationic polyami-doamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009; 10: 258-66.
60. [60] Jeong JH, Mok H, Oh YK, et al. siRNA conjugate delivery systems. Bioconjug Chem 2009; 20: 5-14.
61. [61] Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo deliveryof small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23: 709-17.
62. [62] McNamara JO, Andrechek ER, Wang Y, et al. Cell type-specificdelivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24: 1005-15.
63. [63] Available at https://clinicaltrials.gov/ (Accessed on 26 December2014).
64. [64] Gibbings DJ, Ciaudo C, Erhardt M, et al. Multivesicular bodiesassociate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009; 11: 1143-9.
65. [65] El Andaloussi S, Lakhal S, Mager I, et al. Exosomes for targetedsiRNA delivery across biological barriers. Adv Drug Deliv Rev 2013; 65: 391-7.
66. [66] Subra C, Laulagnier K, Perret B, et al. Exosome lipidomics unrav-els lipid sorting at the level of multivesicular bodies. Biochimie 2007; 89: 205-12.
67. [67] Zhuang X, Xiang X, Grizzle W, et al. Treatment of brain inflamma-tory diseases by delivering exosome encapsulated antiinflammatory drugs from the nasal region to the brain. Mol Ther 2011; 19: 1769-79.
68. [68] Ubra C, Laulagnier K, Perret B, et al. Exosome lipidomics unravelslipid sorting at the level of multivesicular bodies. Biochimie 2007; 89: 205-12.
69. [69] Lasser C. Exosomes in diagnostic and therapeutic applications:biomarker, vaccine and RNA interference delivery vehicle. Expert Opin Biol Ther 2015; 15: 103-17.
70. [70] van den Boorn JG, Schlee M, Coch C, et al. siRNA delivery withexosome nanoparticles. Nat Biotechnol 2011; 29: 325-6.
71. [71] Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to themouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29: 341-5.
72. [72] Wahlgren J, De L Karlson T, Brisslert M, et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 2012; 40: e130.
73. [73] Shtam TA, Kovalev RA, Varfolomeeva EY, et al. Exosomes arenatural carriers of exogenous siRNA to human cells in-vitro. Cell Commun Signal 2013; 11: 88.
74. [74] Kooijmans SA, Stremersch S, Braeckmans K, et al. Electropora-tion-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release 2013; 172: 229-38.
75. [75] Ohno S, Takanashi M, Sudo K, et al. Systemically in-jected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 2013; 21: 185-91.
76. [76] Cooper JM, Wiklander PB, Nordin JZ, et al. Systemic exoso-mal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord 2014; 29: 1476-85.
77. [77] Banizs AB, Huang T, Dryden K, et al. In-vitro evaluation of endo-thelial exosomes as carriers for small interfering ribonucleic acid delivery. Int J Nanomed 2014; 9: 4223-30.
78. [78] Seow Y, Alvarez L, Wood M, inventors. Composition for deliveryof genetic material. World Intellectual Property Organization patent WO 20101-19256 A1 2010.
79. [79] Woods M, Lakhal-Littleton S, Samir El A, inventors. Exosomeswith transferrin peptides. World Intellectual Property Organization patent WO 20130-84 001 A1 2013.
80. [80] Pusic KM, Grinberg YY, Kraig RP, Pusic AD, inventors. Exosome-based therapeutics against neurodegenerative disorder. World Intellectual Property Organization patent WO 20140-28763 A1 2014.
81. [81] Loetvall JO, Valadi H, inventors. Exosome transfer of nucleic acidto cells. World Intellectual Property Organization patent WO 20071-26386 A1 2007.
82. [82] Zeng K, Gu H, Cao M, Li L, Zhang C, inventors. Preparation ofmicrovesicles-siRNA complexes and use thereof in AIDS treatment. European patent EP 257-8236 A1 2013.